Position of the spanish menopause society regarding the management of perimenopause

Maturitas

Volumn 74, Issue 3, 2013, Pages 283-290

  Mendoza, N ^a   Sanchez Borrego R ^b   Cancelo, M J ^c   Calvo, A ^d   Checa, M A ^e   Cortes J ^f   Elorriaga, M A ^g   Diaz T ^h   Gonzalez J V ⁱ   Lete, I ^j   Lobo, P ^k   Martinez Astorquiza T ^g   Nieto, A ^l   Olalla, M A ^m   Perez Campos E ⁿ   Porqueras, R ^o   Quereda, F ^p   Salamanca, A ^q   De La Viuda, E ^c  

^a UNIVERSITY OF GRANADA   (Spain)

^b Clínica Diatros of Barcelona   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

^d HOSPITAL DE MANACOR   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f Hospital de Mallorca   (Spain)

^g HOSPITAL DE CRUCES   (Spain)

^h HOSPITAL DE BASURTO   (Spain)

ⁱ Hospital Militär de Zaragoza   (Spain)

^j HOSPITAL TXAGORRITXU   (Spain)

^k HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^l HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^m Hospital Clínico   (Spain)

ⁿ Hospital de Requena   (Spain)

^o Clinica Tres Torres   (Spain)

^p MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^q HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

more..

Author keywords

Abnormal bleeding; Perimenopause; Screening

Indexed keywords

CANCER SCREENING; CLIMACTERIUM; DIAGNOSTIC TEST; ENDOCRINOLOGY; ENDOMETRIUM BIOPSY; FEMALE FERTILITY; HORMONAL CONTRACEPTION; HUMAN; HYSTEROSCOPY; PREGNANCY; REVIEW; SOCIETY; TRANSVAGINAL ECHOGRAPHY; UTERINE BLEEDING PATTERN; ADULT; AGE; BREAST NEOPLASMS; CONTRACEPTION; EVIDENCE BASED MEDICINE; FEMALE; HOT FLUSH; MASS SCREENING; MENOPAUSE; MENSTRUAL CYCLE; MENSTRUATION DISTURBANCES; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTMENOPAUSE; PRACTICE GUIDELINE; SPAIN; UTERINE CERVICAL NEOPLASMS;

ADULT; AGE FACTORS; BREAST NEOPLASMS; CONTRACEPTION; EVIDENCE-BASED MEDICINE; FEMALE; HOT FLASHES; HUMANS; MASS SCREENING; MENOPAUSE; MENSTRUAL CYCLE; MENSTRUATION DISTURBANCES; MIDDLE AGED; PERIMENOPAUSE; POSTMENOPAUSE; SPAIN; UTERINE CERVICAL NEOPLASMS;

EID: 84875472486     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2012.12.010     Document Type: Review

References (48)

1. Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertility and Sterility 2001;76:874-8.
2. http://www.ine.es/.
3. Burger HG, Hale GE, Robertson DM, Dennerstein L. A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project. Human Reproduction Update 2007;13:559-65.
4. Harlow D, Gass M, Hall JE, et al. STRAW + 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Journal of Clinical Endocrinology and Metabolism 2012;97(4):1159-68.
5. Hale GE, Burger HG. Hormonal changes and biomarkers in late reproductive age, menopausal transition and menopause. Best Practice and Research Clinical Obstetrics and Gynaecology 2009;23:7-23.
6. Yang YS, Hur MH, Kim SY, Young K. Correlation between sonographic and endocrine markers of ovarian aging as predictors for late menopausal transition. Menopause 2011;18:138-45.
7. Sowers MR, Eyvazzadeh AD, McConnell D, et al. Anti-Mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. Journal of Clinical Endocrinology and Metabolism 2008;93:3478-83.
8. Munro MG, Critchley HO, Broder MS, Fraser IS, FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. International Journal of Gynaecology and Obstetrics 2011;113(1):3-13.
9. Marret H, Fauconnier A, Chabbert-Buffet N, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2010;152(2):133-7.
10. Avis NE, Colvin A, Bromberger JT, et al. Change in health-related quality of life over the menopausal transition in a multiethnic cohort of middle-aged women: Study of Women's Health Across the Nation (SWAN). Menopause 2009;16(5):860-9.
11. Hess R, Conroy MB, Ness R, et al. Association of lifestyle and relationship factors with sexual functioning of women during midlife. Journal of Sex Medicine 2009;6(5):1358-68.
12. Mac Dougall K, Beyene Y, Nachtigall RD. Age shock: misperceptions of the impact of age on fertility before and after IVF in women who conceived after age 40. Human Reproduction 2012 [Epub ahead of print].
13. Krieg SA, Henne MB, Westphal LM. Obstetric outcomes in donor oocyte pregnancies compared with advanced maternal age in in Vitro fertilization pregnancies. Fertility and Sterility 2008;90(1):65-70.
14. Loane M, Dolk H, Morris JK. EUROCAT Working Group: maternal age-specific risk of non-chromosomal anomalies. BJOG 2009;116:1111-9.
15. Bayrampour H, Heaman M. Advanced maternal age and the risk of cesarean birth: a systematic review. Birth 2010;37:219-26.
16. www.sec.es.
17. Farquar C, Brown J. Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database System Review 2009;4:CD000154.
18. Blumel JE, Casterlo-Branco C, Binfa L, Aparcicio R, Mamani L. A scheme of combined oral contraceptives for women more than 40 years old. Menopause 2001;8:286-9.
19. Cibula D, Gompel A, Mueck AO, et al. Hormonal contraception and risk of cancer. Human Reproduction Update 2010;16(6):631-50.
20. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890.
21. Marret H, Fauconnier A, Chabbert-Buffet N, et al. CNGOF Collège National des Gynécologues et Obstétriciens Français. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. European Journal of Obstetrics, Gynecology and Reproduction Biology 2010;152(2):133-7.
22. Endrikat J, Shapiro H, Lukkari-Lax E, Kunz M, Schmidt W, Fortier M. A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. Journal of Obstetrics and Gynaecology Canada 2009;31:340-7, 29 National Institute for Health and Clinical Excellence. Heavy Menstrual Bleeding (NICE Clinical Guideline 44). 2007.
23. Chakhtoura Z, Canonico M, Gompel A, Thalabard JC, Plu-Bureau G. Progestogen-only contraceptives and risk of stroke: a meta-anlaysis. Stroke 2009;40:1059-62.
24. Lete I, Bermejo R, Parrilla JJ, et al. Use of contraceptive methods and risk of unwanted pregnancy in Spanish women aged 40-50 years: results of a survey conducted in Spain. European Journal of Contraception and Reproductive Health Care 2007;12:46-50.
25. Desreux J, Bleret V, Lifrange E. Should we individualize breast cancer screening? Maturitas 2012;73(3):202-5.
26. Leeper AD, Dixon JM. DCIS of the breast: are we over-diagnosing it? Are we over-treating it? Maturitas 2011;68(4):295-6.
27. Meissner HI, Klabunde CN, Breen N, Zapka JM. Breast and colorectal cancer screening: US Primary care physicians' reports of barriers. American Journal of Preventive Medicine 2012;43(December (6)):584-9.
28. Endometrial cancer in women 45 years of age or younger: A clinicopathological analysis. Gilbert P. Pellerin, Michael A. Finan. AJOG 2005; 193: 1640-4.
29. Cortés J. Prevención primaria y secundaria de los cánceres de cuello de útero y vulva: recomendaciones para la práctica clínica. Program in Obstetrics Gynecology 2010;53(Suppl. 1):1-19.
30. De Sanjose S, Díaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infectious Diseases 2007;7:453-9.
31. Wellings K, Collumbien M, Slaymaker E, et al. Sexual behaviour in context: a global perspective. Lancet 2006;368:1706-28;.
32. Muñoz N, Manalastas Jr R, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009;373:1949-57.
33. Castellsagué X, Muñoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. British Journal of Cancer 2011;105:28-37.
34. Goldstein SR. Modern evaluation of the endometrium. Obstetrics and Gynecology 2010;116:168-76.
35. Van Dongen H. A randomised comparison of vaginoscopic office hysteroscopy and saline infusion sonography: a patient compliance study. BJOG 2008;115:1232-57.
36. Davis SR, Castelo-Branco C, Chedraui P, et al. Writing group of the international menopause society for world menopause day 2012. Understanding weight gain at menopause. Climacteric 2012;15(5):419-29.
37. Collins P, Rosano G, Casey C, et al. Management of cardiovascular disease risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. European Heart Journal 2007;28:2018-40.
38. Chaudhry S, Berkley C, Warren M. Perimenopausal vaginal bleeding: diagnostic evaluation and therapeutic options. Journal of Womens Health (Larchmt) 2012;21(3):302-10.
39. Daley A, Stokes-Lampard H, Macarthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database System Review 2011;11(5):CD006108.
40. Coiro V, Volpi R, Gramellini D, Maffei, et al. Effect of physical training on agerelated reduction of GH secretion during exercise in normally cycling women. Maturitas 2010;65(4):392-5.
41. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database System Review 2012;7:CD004143.
42. Worsley R, Davis SR, Gavrilidis E, et al. Hormonal therapies for new onset and relapsed depression during perimenopause. Maturitas 2012;73(2):127-33.
43. Krebs EE, Ensrud KE, MacDonald R, Wilt TJ. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstetrics and Gynecology 2004;104:824.
44. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database System Review 2012 Sep 12;9:CD007244.
45. Thomas HM, Bryce CL, Ness RB, Hess R. Dyspareunia is associated with decreased frequency of intercourse in the menopausal transition. Menopause 2011;18(2):152-7.
46. Gupta S, Gabrani R, Ali J, Dang S. Exploring novel approaches to vaginal drug delivery. Recent Patents on Drug Delivery and Formulation 2011;5(2):82-94.
47. Kadian S, O'Brien S. Classification of premenstrual disorders as proposed by the International Society for Premenstrual Disorders. Menopause International 2012;18(2):43-7.
48. http://cebgrade.mcmaster.ca/.